June 4, 2020 -- The company's technology for improving industrial microorganisms can be used to increase the productivity of host cells needed to produce COVID-19 vaccines, according to Evolugate. As a result, vaccine manufacturers will be able to reduce the time it takes to make each dose and to get the vaccines to market, the firm said.
Evolugate has already begun to grow and improve the productivity of insect SF9 cells -- a critical component for one of the potential COVID-19 vaccines. It also intends to expand its COVID-19 Host Cell Program to include at least four other critical cell lines commonly utilized for producing vaccines.
What's more, Evolugate is exploring potential partnerships with pharmaceutical companies and governmental agencies to support and accelerate the program.
Image courtesy of Evolugate.
Copyright © 2020 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
